Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anamorelin with enfortumab vedotin + pembrolizumab for advanced or metastatic urothelial carcinoma
jRCTs041250214Recruiting
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of anamorelin in transitional cell carcinoma (TCC). Primary endpoint: Clinically significant weight loss over 24 weeks. Started Aug 2026; status: recruiting.
02
Drugs
anamorelin
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on jRCTs041250214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041250214.